Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free RDY Stock Alerts

Dr. Reddy's Laboratories (RDY) Competitors

Dr. Reddy's Laboratories logo
$13.36 +0.06 (+0.42%)
Closing price 06/11/2026 03:59 PM Eastern
Extended Trading
$13.36 0.00 (-0.01%)
As of 07:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

RDY vs. TEVA, RVMD, ONC, BNTX, and ROIV

Should you buy Dr. Reddy's Laboratories stock or one of its competitors? MarketBeat compares Dr. Reddy's Laboratories with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dr. Reddy's Laboratories include Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), BeOne Medicines (ONC), BioNTech (BNTX), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

How does Dr. Reddy's Laboratories compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

In the previous week, Teva Pharmaceutical Industries had 34 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 34 mentions for Teva Pharmaceutical Industries and 0 mentions for Dr. Reddy's Laboratories. Teva Pharmaceutical Industries' average media sentiment score of 1.22 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Overall Sentiment
Teva Pharmaceutical Industries Positive
Dr. Reddy's Laboratories Neutral

Teva Pharmaceutical Industries has higher earnings, but lower revenue than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.30$1.41B$1.3325.98
Dr. Reddy's Laboratories$335.93B0.03$456M$0.5823.03

Teva Pharmaceutical Industries currently has a consensus price target of $41.78, indicating a potential upside of 20.92%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries9.01% 43.53% 8.19%
Dr. Reddy's Laboratories 12.90%12.34%8.24%

Summary

Teva Pharmaceutical Industries beats Dr. Reddy's Laboratories on 12 of the 16 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Revolution Medicines?

Dr. Reddy's Laboratories (NYSE:RDY) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Dr. Reddy's Laboratories has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$335.93B0.03$456M$0.5823.03
Revolution Medicines$11.58M2,739.75-$1.13B-$7.07N/A

Revolution Medicines has a consensus target price of $123.72, suggesting a potential downside of 17.09%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Revolution Medicines is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Revolution Medicines
1 Sell rating(s)
1 Hold rating(s)
17 Buy rating(s)
3 Strong Buy rating(s)
3.00

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Revolution Medicines' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories12.90% 12.34% 8.24%
Revolution Medicines N/A -83.22%-59.06%

In the previous week, Revolution Medicines had 5 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for Revolution Medicines and 0 mentions for Dr. Reddy's Laboratories. Revolution Medicines' average media sentiment score of 1.16 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company Overall Sentiment
Dr. Reddy's Laboratories Neutral
Revolution Medicines Positive

3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Summary

Revolution Medicines beats Dr. Reddy's Laboratories on 10 of the 17 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

BeOne Medicines presently has a consensus price target of $390.00, indicating a potential upside of 49.84%. Given BeOne Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe BeOne Medicines is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeOne Medicines
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Dr. Reddy's Laboratories has higher revenue and earnings than BeOne Medicines. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeOne Medicines$5.34B5.34$286.93M$4.4758.23
Dr. Reddy's Laboratories$335.93B0.03$456M$0.5823.03

In the previous week, BeOne Medicines had 13 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 13 mentions for BeOne Medicines and 0 mentions for Dr. Reddy's Laboratories. BeOne Medicines' average media sentiment score of 0.02 beat Dr. Reddy's Laboratories' score of 0.00 indicating that BeOne Medicines is being referred to more favorably in the media.

Company Overall Sentiment
BeOne Medicines Neutral
Dr. Reddy's Laboratories Neutral

BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to BeOne Medicines' net margin of 8.94%. Dr. Reddy's Laboratories' return on equity of 12.34% beat BeOne Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
BeOne Medicines8.94% 12.06% 6.69%
Dr. Reddy's Laboratories 12.90%12.34%8.24%

Summary

BeOne Medicines beats Dr. Reddy's Laboratories on 12 of the 17 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to BioNTech?

Dr. Reddy's Laboratories (NYSE:RDY) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Dr. Reddy's Laboratories has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$335.93B0.03$456M$0.5823.03
BioNTech$3.25B6.98-$1.29B-$5.88N/A

3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, BioNTech had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for BioNTech and 0 mentions for Dr. Reddy's Laboratories. BioNTech's average media sentiment score of 0.69 beat Dr. Reddy's Laboratories' score of 0.00 indicating that BioNTech is being referred to more favorably in the news media.

Company Overall Sentiment
Dr. Reddy's Laboratories Neutral
BioNTech Positive

BioNTech has a consensus target price of $129.56, indicating a potential upside of 44.70%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
BioNTech
1 Sell rating(s)
4 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.74

Dr. Reddy's Laboratories has a net margin of 12.90% compared to BioNTech's net margin of -44.39%. Dr. Reddy's Laboratories' return on equity of 12.34% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories12.90% 12.34% 8.24%
BioNTech -44.39%-5.30%-4.62%

Summary

BioNTech beats Dr. Reddy's Laboratories on 10 of the 17 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Roivant Sciences?

Dr. Reddy's Laboratories (NYSE:RDY) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Dr. Reddy's Laboratories has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$335.93B0.03$456M$0.5823.03
Roivant Sciences$8.26M2,588.85-$299.77M-$0.60N/A

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Roivant Sciences' net margin of -3,629.19%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Roivant Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories12.90% 12.34% 8.24%
Roivant Sciences -3,629.19%-20.54%-19.43%

3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dr. Reddy's Laboratories has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

In the previous week, Roivant Sciences had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 11 mentions for Roivant Sciences and 0 mentions for Dr. Reddy's Laboratories. Roivant Sciences' average media sentiment score of 1.33 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Dr. Reddy's Laboratories Neutral
Roivant Sciences Positive

Roivant Sciences has a consensus price target of $33.59, suggesting a potential upside of 12.99%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Roivant Sciences
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

Roivant Sciences beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

Get Dr. Reddy's Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RDY vs. The Competition

Export
MetricDr. Reddy's LaboratoriesMED IndustryMedical SectorNYSE Exchange
Market Cap$11.10B$5.80B$6.46B$22.83B
Dividend Yield0.53%0.68%2.67%4.10%
P/E Ratio23.038.7724.1731.02
Price / Sales0.0320.87534.0521.39
Price / Cash15.708.3943.2023.95
Price / Book2.754.0910.564.68
Net Income$456M$99.67M$3.56B$1.07B
7 Day Performance0.69%-1.25%0.22%1.53%
1 Month Performance7.26%2.82%0.66%1.32%
1 Year Performance-17.25%125.74%22.16%21.42%

Dr. Reddy's Laboratories Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RDY
Dr. Reddy's Laboratories
1.3476 of 5 stars		$13.36
+0.4%		N/A-16.1%$11.10B$335.93B23.0327,527
TEVA
Teva Pharmaceutical Industries
4.5227 of 5 stars		$34.16
+1.7%		$41.78
+22.3%		+99.7%$39.25B$17.35B25.6733,950
RVMD
Revolution Medicines
1.7722 of 5 stars		$144.59
+0.3%		$123.72
-14.4%		+265.8%$30.59BN/AN/A250
ONC
BeOne Medicines
4.1232 of 5 stars		$257.39
-2.4%		$390.00
+51.5%		-0.8%$28.24B$5.34B57.5912,000
BNTX
BioNTech
4.3788 of 5 stars		$86.32
+0.2%		$129.56
+50.1%		-15.1%$21.78B$2.81BN/A7,807

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:RDY) was last updated on 6/12/2026 by MarketBeat.com Staff.
From Our Partners
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Is your wealth prepared for “America’s Most Dangerous Man”? (Read before June 16)
60-year Wall Street veteran Marc Chaikin is issuing an urgent warning about the billionaire behind an AI lab t...
Chaikin Analytics | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
SMX Could Turn Proof Technology into Major Profit!
SMX (Security Matters) PLC embeds invisible molecular markers into plastics, metals, fuels, and textiles, link...
Smallcaps Daily | Sponsoredtc pixel
VWAV: Is This the Next Defense Breakout?
VisionWave Holdings, Inc. (NASDAQ: VWAV) is developing a full-stack defense technology platform that integrate...
Equiscreen | Sponsoredtc pixel
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...
Behind the Markets | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel